Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Robert A. Anders

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2363-9072; OpenAlex author ID A5025711714, A5109602083; NIH RePORTER profile ID 7735151. Sources: OpenAlex.

Their work

Papers
34 (first author 1, last author 2)
Trials
0
Grants
1
Labs led
1
Collaborators
147
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 3 papers · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 4 papers · 2021: 2 papers · 2022: 3 papers, 1 grant · 2023: 1 paper · 2024: 3 papers · 2025: 4 papers · 2026: 6 papers

Papers 34

  1. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Co-author DOI 10.1038/s41467-026-68324-4↗
  2. The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II… Co-author DOI 10.1038/s41467-026-69294-3↗
  3. Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial Co-author DOI 10.1038/s41467-026-71968-x↗
  4. Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics. Co-author DOI 10.1136/gutjnl-2025-335683↗
  5. A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC. Co-author DOI 10.1158/2326-6066.cir-25-0545↗
  6. Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer. Co-author DOI 10.1172/jci190121↗
  7. CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer clinical trial. Co-author DOI 10.1016/j.isci.2024.111569↗
  8. A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrop… Co-author DOI 10.1080/2162402x.2025.2543614↗
  9. Spatial profiling of human pancreatic ductal adenocarcinoma reveals molecular alterations associated with venous invasion. Co-author DOI 10.1126/scitranslmed.ady7524↗
  10. A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-24-3403↗
  11. Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic resp… Co-author DOI 10.1101/2024.09.22.613714↗
  12. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Co-author DOI 10.1126/sciadv.adk1827↗
  13. SREBP-Dependent Regulation of Lipid Homeostasis Is Required for Progression and Growth of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2767-9764.crc-24-0120↗
  14. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with r… Co-author DOI 10.1038/s41467-023-39196-9↗
  15. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Co-author DOI 10.1016/j.ccell.2022.10.001↗
  16. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  17. Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications. Last author DOI 10.3389/fonc.2022.809179↗
  18. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  19. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  20. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-019-0683-3↗
  21. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3978↗
  22. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1025↗
  23. Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development. First author DOI 10.1158/1940-6207.capr-20-0053↗
  24. Targeting Mechanoresponsive Proteins in Pancreatic Cancer: 4-Hydroxyacetophenone Blocks Dissemination and Invasion by Activating MYH14. Co-author DOI 10.1158/0008-5472.can-18-3131↗
  25. Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-18-0367↗
  26. Harnessing the adaptive potential of mechanoresponsive proteins to overwhelm pancreatic cancer dissemination and invasion Co-author DOI 10.1101/190553↗
  27. Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment. Co-author DOI 10.1158/1535-7163.mct-16-0452↗
  28. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000001600↗
  29. Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation. Co-author DOI 10.1158/0008-5472.can-15-3264↗
  30. Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. Last author DOI 10.1158/2326-6066.cir-15-0200-t↗
  31. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. Co-author DOI 10.1111/hpb.12334↗
  32. Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. Co-author DOI 10.1126/scisignal.aaa5823↗
  33. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. Co-author DOI 10.3791/4059↗
  34. Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0019390↗

Grants 1

  1. Core 2: Biospecimen/Pathology Core P50CA062924↗

Closest collaborators

The 25 strongest of 147 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elizabeth M. Jaffee · 26 shared papers, 1 shared grant, 2011–2026 · strength 3.25
  2. Lei Zheng · 20 shared papers, 2011–2026 · strength 1.89
  3. Daniel A. Laheru · 17 shared papers, 2011–2026 · strength 1.85
  4. Elana Judith Fertig · 10 shared papers, 2020–2026 · strength 1.51
  5. Hao Wang · 8 shared papers, 2022–2026 · strength 1.42
  6. Dung Thi Le · 11 shared papers, 2011–2026 · strength 1.25
  7. Won Jin Ho · 7 shared papers, 2020–2026 · strength 1.19
  8. Katherine M. Bever · 8 shared papers, 2013–2026 · strength 1.05
  9. Janelle Marie Montagne · 6 shared papers, 2022–2026 · strength 1.02
  10. Amol Kumar Narang · 7 shared papers, 2021–2026 · strength 0.96
  11. Luciane Tsukamoto Kagohara · 5 shared papers, 2024–2026 · strength 0.89
  12. Jin Peng He · 7 shared papers, 2021–2025 · strength 0.84
  13. Arsen Osipov · 5 shared papers, 2021–2026 · strength 0.74
  14. Ana De Jesus‐Acosta · 7 shared papers, 2015–2025 · strength 0.72
  15. Mark M. Yarchoan · 4 shared papers, 2024–2026 · strength 0.71
  16. Jacob T. Mitchell · 4 shared papers, 2022–2026 · strength 0.71
  17. Richard Andrew Burkhart · 5 shared papers, 2021–2026 · strength 0.70
  18. Jacquelyn W. Zimmerman · 4 shared papers, 2020–2026 · strength 0.64
  19. Nilofer Saba Azad · 5 shared papers, 2021–2026 · strength 0.64
  20. Ralph H. Hruban · 3 shared papers, 1 shared grant, 2016–2026 · strength 0.63
  21. Jae Woo Lee · 3 shared papers, 2026 · strength 0.61
  22. Amanda L. Huff · 3 shared papers, 2026 · strength 0.61
  23. Thatcher Ross Heumann · 4 shared papers, 2022–2026 · strength 0.61
  24. Valerie Lee · 4 shared papers, 2021–2026 · strength 0.54
  25. Anirban Maitra · 4 shared papers, 1 shared grant, 2011–2022 · strength 0.51

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.